

Active control (standard of care) + IYCF counselling											control	control	control	control						
Zimbabwe	2013-2017	SHINE	cluster RCT; longitudinal follow-up	Humphrey, 2019 (47); Prendergast, 2019 (48) ¹	IYCF; child SQ LNS + IYCF counselling	Sub-study included infants of women reaching 32 weeks' gestation visit from 1 May 2014 through the end of the trial; all HIV exposed infants included	Dependent on age	Y	∇ ²	∇ ³	-----	∇ ⁴	-----	-----	-----	-----	LNS	LNS	LNS	LNS
WASH: Family received ventilated improved pit latrine, handwashing stations, soap, chlorine, child play space											control	control	control	control						
WASH and IYCF: child SQ LNS + IYCF counselling, family received ventilated improved pit latrine, handwashing stations, soap, chlorine, child play space											LNS	LNS	LNS-WSH	LNS						
Active control (standard of care)											control	control	control	control						

IFA, iron-folic acid; IYCF, infant and young child feeding; LNS, lipid-based nutrient supplement; MMN, multiple micronutrients; MNP, multiple micronutrient powder; MQ LNS, medium-quantity lipid-based nutrient supplement; ORS, oral rehydration solution; SQ LNS, small-quantity lipid-based nutrient supplement; WASH, water sanitation and hygiene; WSB, wheat soy blend; RCT, randomized controlled trial.

¹All supplements were isocaloric; children 6-12 mo received 125 kcal/d; children 13-18 mo received 250 kcal/d

²All children in the four intervention groups received ORS for diarrhea and treatment for malaria

³Data not yet available

⁴Trial is cited as Kumwenda 2014 in Das et al. [Cochrane Database of Systematic Reviews 2019]

⁵Trial was designed in order to present results separately for HIV-exposed and un-exposed children; thus considered as two comparisons in all analyses and the presentation of results

Supplemental Table 1. Amount of LNS provided (g/day) and nutrient value (per daily ration)

	Nutributter ¹	iLiNS formulation ^{2,3}	Revised iLiNS formulation ⁴	Plumpy'Doz (6-11 mo) ⁵	Plumpy'Doz (12-18 mo) ⁵	Rice-lentil LNS (6-11 mo) ⁵	Rice-lentil LNS (12-18 mo) ⁵	Chickpea LNS (6-11 mo) ⁵	Chickpea LNS (12-18 mo) ⁵
Ration (g/day)	20	20	20	23.2	46.4	25.7	51.4	23.6	47.2
Total energy (kcal)	108	118	118	123.4	246.8	133.9	267.8	128.6	257.2
Protein (g)	2.56	2.6	2.6	2.9	5.9	2.8	5.7	3.5	7.1
Fat (g)	7.08	9.6	9.6	7.9	15.8	6.9	13.9	6.6	13.2
Linoleic acid (g)	1.29	4.46	4.46						
α-Linolenic acid (g)	0.29	0.58	0.58						
Vitamin A (µg RE)	400	400	400	200	400	117.7	235.4	118.5	236.9
Vitamin C (mg)	30	30	30						
Vitamin B1 (mg)	0.3	0.3	0.5	0.3	0.5	0.3	0.6	0.3	0.6
Vitamin B2 (mg)	0.4	s	0.5	0.3	0.5	0.2	0.5	0.2	0.5
Niacin (mg)	4	4	6	2.8	5.6	2.6	5.1	2.4	4.7
Folic acid (µg)	80	80	150	80	160.1	100	199.9	118.2	236.5
Pantothenic acid (mg)	1.8	1.8	2	1	2	1.1	2.2	1	2
Vitamin B6 (mg)	0.3	0.3	0.5	0.3	0.5	0.3	0.6	0.3	0.6
Vitamin B12 (µg)	0.5	0.5	0.9	0.4	0.8	0.5	0.9	0.5	0.9
Vitamin D (IU) 1 IU = 0.025 µg	0	200	200			226.2	452.3	226.6	453.1
Vitamin E (mg)	0	6	6	3	6	4.9	9.8	4.7	9.4
Vitamin K (µg)	0	30	30			11.3	22.6	11.3	22.7
Iron (mg)	9	6	9	4.5	9	3.3	6.7	3.5	7.1
Zinc (mg)	4	8	8	2	4	2.4	4.8	2.5	5.1
Copper (mg)	0.2	0.34	0.34	0.2	0.3	0.2	0.4	0.3	0.5
Calcium (mg)	100	280	280	193.5	387	208.2	416.3	219.5	439
Phosphorus (mg)	82	190	190	137.6	275.2	61.7	123.4	72.9	145.8
Potassium (mg)	152	200	200	155	310	206.6	413.3	220.7	441.3
Magnesium (mg)	16	40	40	29.9	59.9	41.6	83.3	47.7	95.3
Selenium (µg)	10	20	20	8.6	17.2	7.5	14.9	7.6	15.1
Iodine (µg)	90	90	90	27.6	55.2	33.7	67.3	33.7	67.5
Manganese (mg)	0.08	1.2	1.2	0.1	0.1	0.5	0.9	0.4	0.9

¹Provided by Adu-Afarwuah 2007 (40)

²Provided by Hess 2015 (38), Becquey 2019 (39), Adu-Afarwuah 2016 (41), Galasso 2019 (43), Ashorn 2015 (44), Maleta 2015 (45), Huybregts 2019 (46), Humphrey 2019 (47), Prendergast 2019 (48).

³Hess 2015 (38) provided 0-10 mg zinc/d in the SQ-LNS product, plus a 5 mg/d zinc supplement in one intervention arm. Maleta 2015 (45) provided 10-40 g/d of LNS, with and without milk powder, varying by intervention arm (the 40 g arms were not included in this IPD analysis); the micronutrient composition of the LNS was identical across intervention arms, but there were differences in total kcal, protein, fat, linoleic acid and α-linolenic acid.

⁴Provided by Dewey 2017 (36), Luby 2018 (37), Null 2018 (42)

⁵Provided by Christian 2015 (35). Product and quantities differed by intervention arm and age.

Supplemental Table 3: Descriptive information on potential study-level effect modifiers, by trial

Country	Author	Geographic Region	Malaria Prevalence (%)	Anemia Prevalence (%)	Inflammation (CRP > 5 mg/L)	Inflammation AGP > 1 g/L	Water quality (% improved)	Sanitation (% improved)	Duration of supplementation	Iron dose (mg/d)	Frequency of contact	Average SQ-LNS compliance (%)	Compliance definition (in the SQ-LNS group)	Source (Anemia prevalence)
Bangladesh	Christian, 2015 (35); Campbell, 2020 (15)	SEAR	0.2 ^a	53.3% ^a	21% ^b	59% ^b	100.0 ^c	77.0 ^d	< 12 mo	3.3-9 mg/d ^e	Weekly	93.0 ^f	% of total intended SQ-LNS consumed (quantity * day)	National Institute of Population Research and Training (NIPORT), Mitra and Associates, and ICF International. 2011. Bangladesh Demographic and Health Survey 2011. Dhaka, Bangladesh and Calverton, Maryland, USA. NIPORT, Mitra and Associates, and ICF International. 2011.
Bangladesh	Dewey, 2017 (36); Malina, 2018 (10)	SEAR	0.2 ^a	51.3% ^a	14% ^b	32% ^b	100.0 ^c	71.1 ^d	> 12 mo	9 mg/d	Monthly	97.4 ^f	% reporting "high adherence (≥ 4 days/week)	Bangladesh Demographic and Health Survey 2011. Dhaka, Bangladesh and Calverton, Maryland, USA. NIPORT, Mitra and Associates, and ICF International. 2011.
Bangladesh	Luby, 2018 (37); Stewart, 2019 (12)	SEAR	0.1 ^a	51.3% ^a	11% ^b	29% ^b	88.5 ^c	94.7 ^d	> 12 mo	9 mg/d	Weekly	93.0 ^f	Number of sachets consumed in 14 days prior to annual survey/14	Bangladesh Demographic and Health Survey 2011. Dhaka, Bangladesh and Calverton, Maryland, USA. NIPORT, Mitra and Associates, and ICF International. 2011.
Burkina Faso	Hess, 2015 (38); Abbeduto 2017 (11)	AFR	59.1 ^a	87.8% ^a	32% ^b	59% ^b	26.7 ^c	2.3 ^d	< 12 mo	6 mg/d	Weekly	96.8 ^f	% of days SQ-LNS reported consumed caregiver reported receiving SQ-LNS in the previous month	Institut National de la Statistique et de la Démographie (INSD) et ICF International. 2012. Enquête Démographique et de Santé et à Indicateurs Multiples du Burkina Faso 2010. Calverton, Maryland, USA. INSD et ICF International.
Burkina Faso	Bequey, 2019 (39) ^g	AFR	42.9 ^a	87.8% ^a	---	---	50.6 ^c	53.4 ^d	< 12 mo	6 mg/d	Monthly	37.0 ^f	% of days SQ-LNS reported consumed	Ghana Statistical Service (GSS), Noguchi Memorial Institute for Medical Research (NMMRI), and ORC Macro. 2004. Ghana Demographic and Health Survey 2008. Calverton, Maryland, USA. INSD et ICF International.
Ghana	Adu-Afarwah, 2007 (40); Adu-Afarwah, 2008 (9)	AFR	37.4 ^a	76.1% ^a	18% ^b	---	91.9 ^c	91.5 ^d	< 12 mo	9 mg/d	Weekly	88.2 ^f	% of days SQ-LNS reported consumed	Ghana Statistical Service, 2011. Ghana Multiple Indicator Cluster Survey with an Enhanced Malaria Module and Biomarker, 2011. Final Report. Accra, Ghana.
Ghana	Adu-Afarwah, 2016 (41); Adu-Afarwah, 2019 (16)	AFR	36.8 ^a	57.0% ^a	18% ^b	44% ^b	98.4 ^c	97.3 ^d	< 12 mo	6 mg/d	Weekly	71.5 ^f	% of days SQ-LNS reported consumed	National Malaria Control Programme (NMCP), Kenya National Bureau of Statistics (KNBS), and ICF International. 2016. Kenya Malaria Indicator Survey 2015. Nairobi, Kenya, and Rockville, Maryland, USA. NMCP, Kenya, and ICF International.
Kenya	Nuli, 2018 (42); Stewart, 2019 (12)	AFR	8.5 ^a	36.3% ^a	21% ^b	47% ^b	68.0 ^c	15.8 ^d	> 12 mo	9 mg/d	Monthly	115.0 ^f	Number of sachets consumed in 14 days prior to annual survey/14	National Statistical Office (NSO) and ICF Macro. 2011. Malawi Demographic and Health Survey 2010. Zomba, Malawi, and Calverton, Maryland, USA. NSO and ICF Macro.
Madagascar	Galasso, 2019 (43); Stewart, 2020 (13)	AFR	5.5 ^a	53.0% ^a	19% ^b	41% ^b	26.9 ^c	0.0 ^d	< 12 mo	6 mg/d	Monthly	-	Data unavailable.	Institut National de la Statistique (INSTAT), Programme National de Lutte contre le Paludisme (PNLP), Institut Pasteur de Madagascar (IPM) et ICF International. 2013. Enquête sur les Indicateurs de Pollution (EIPM) 2013. Calverton, MD, USA - National Statistical Office (NSO) and ICF Macro. 2011. Malawi Demographic and Health Survey 2010. Zomba, Malawi, and Calverton, Maryland, USA. NSO and ICF Macro.
Malawi	Achorn, 2015 (44)	AFR	26.8 ^a	62.5% ^a	30% ^b	68% ^b	91.7 ^c	9.2 ^d	< 12 mo	6 mg/d	Weekly	77.1 ^f	% of days SQ-LNS reported consumed	National Statistical Office (NSO) and ICF Macro. 2011. Malawi Demographic and Health Survey 2010. Zomba, Malawi, and Calverton, Maryland, USA. NSO and ICF Macro.
Malawi	Malata, 2015 (45)	AFR	30.3 ^a	62.5% ^a	34% ^b	66% ^b	91.6 ^c	2.9 ^d	< 12 mo	6 mg/d	Weekly	71.6 ^f	% of days SQ-LNS reported consumed (considering missed delivery visits)	National Statistical Office (NSO) and ICF Macro. 2011. Malawi Demographic and Health Survey 2010. Zomba, Malawi, and Calverton, Maryland, USA. NSO and ICF Macro.
Mali	Haybregts, 2019 (46) ^g	AFR	39.1 ^a	81.8% ^a	---	---	50.8 ^c	75.3 ^d	> 12 mo	6 mg/d	Monthly	47.0 ^f	caregiver reported receiving SQ-LNS in the previous month	Institut National de la Statistique (INSTAT), Cellule de Planification et de Statistique Secteur Santé-Développement Social et Promotion de la Famille (CPS/S/S-D5-PP), et ICF. 2016. Sixième Enquête Démographique et de Santé au Mali 2018.
Zimbabwe	Humphrey, 2019 (47); Proendrgast 2019 (48) ^g	AFR	9.0 ^a	36.8% ^a	21% ^b	---	63.6 ^c	81.0 ^d	< 12 mo	6 mg/d	Monthly	73.3 ^f	received ≥ 11 (80% of expected) deliveries * consumed SQ-LNS in past 28 h (at 12 month visit)	Zimbabwe National Statistics Agency and ICF International. 2016. Zimbabwe Demographic and Health Survey 2015: Final Report. Rockville, Maryland, USA. Zimbabwe National Statistics Agency (ZIMSTAT) and ICF International.

AFR, Africa Region; AGP, alpha-1 acid glycoprotein; CRP, C-reactive protein; SEAR, South East Asia Region; SQ-LNS, small quantity lipid-based nutrient supplements

¹Iron dose varied by age and SQ-LNS intervention group (see Supplemental Table 2)

²Study-level effect modifier categorization based on the longitudinal cohort, for consistency with the growth and development domains of this individual participant data analysis

³Study-level effect modifier categorization was the same for both HIV exposed and HIV un-exposed children

Superscripts a and b designate the two categories, as described in Notes below.

Notes:

Geographic region: based on WHO regions

Malaria prevalence: Data extracted from *Anemia, Data Table F: Population at risk and re-estimated malaria cases and deaths, 2010-2017 (wmr2018-annex-table-f.xls)*; Point estimate (presumed and confirmed malaria cases), divided by population at risk, per 100 persons. Trials were categorized as (a) low burden when malaria was < 5% and (b) high burden when malaria was ≥ 5%.

Prevalence of anemia: Data extracted from *DESI/MCS, survey dosist in time to the start of child supplementation; prevalence of Hb < 110 g/L among children 6-59 months (sources cited in table)*. Trials were categorized as (a) moderate burden when anemia was < 60% and (b) high burden when anemia was ≥ 60%.

Inflammation was defined as CRP > 5 mg/L and AGP > 1 g/L. Prevalence of inflammation was based on study-specific data at outcome assessment. Inflammation was defined as (a) low burden when high CRP prevalence < 25% and high AGP < 50%, and (b) high burden when high CRP prevalence > 25% or high AGP > 50%.

Water quality: Data based on sample prevalences of improved source water quality. Study-level water quality was considered as (a) improved if the main source of drinking water for ≥ 70% of participants was improved. "Improved water sources are those that have the potential to deliver safe water by nature of their design and construction, and include: piped water, boreholes or tubewells, protected dug wells, protected springs, rainwater and packaged or delivered water". Unimproved water sources include: water from an unprotected dug well or unprotected spring, or surface water (e.g., river, dam, lake, pond, stream, canal or irrigation canal). (<https://washdata.org/monitoring/sanitation>)

Sanitation: Data based on sample prevalences of improved sanitation. Study-level sanitation was considered as (a) improved if sanitation services for ≥ 50% of participants were improved; study-level sanitation was considered as (b) unimproved if sanitation services for < 50% of participants were improved. "Improved sanitation facilities are those designed to hygienically separate excreta from human contact, and include: flush/pour flush to piped sewer system, septic tanks or pit latrines; ventilated improved pit latrines, composting toilets or pit latrines with slabs". Unimproved sanitation services include: use of pit latrines without a slab or platform, hanging latrines or bucket latrines, or open defecation. (<https://washdata.org/monitoring/sanitation>)

Compliance: Data extracted from publication; study-specific definitions of compliance are noted in the table. Trials were categorized as (a) high compliance when compliance was ≥ 80% or (b) low compliance when compliance was < 80% compliance.

References

World Malaria Report 2018. Geneva: World Health Organization, 2018. Available at: <https://www.who.int/malaria/publications/world-malaria-report-2018/report/en/>

Supplemental Table 4: Descriptive information on potential individual-level effect modifiers, by trial

Country	Author	Maternal BMI < 20 kg/m ² (%)	Maternal age < 25 y (%)	Maternal education, completed primary (%)	Child sex, male (%)	Child birth order, first born (%)	Prevalence of baseline anemia (%)	Prevalence of baseline acute malnutrition (%)	Inflammation at endline (%)	Receipt of high-dose vitamin A (%)	Baseline food security, moderate/severe insecurity (%)	SES index, below median (%)	Improved source water quality (%)	Improved sanitation access (%)	Season at endline, dry (%)
Bangladesh	Christian, 2015 (35); Campbell, 2020 (15)		54.2	65.2	50.8	75.4*		20.3	61.3	50.6	24.9 ^a	46.3	100.0	79.3	55.6
Bangladesh	Dewey, 2017 (36); Matias, 2018 (10)	58.2	71.7	73.1	48.5	37.8	60.8	6.0	34.5	81.2	38.2 ^b	50.2	100.0	69.3	61.8
Bangladesh	Luby, 2018 (37); Stewart, 2019 (12)	51.4	58.9	73.3	48.8	37.5			22.8	60.3	20.2 ^b	50.7	78.8	92.5	48.6
Burkina Faso	Hess, 2015 (38); Abbeduto, 2017 (11)	38.8	41.3	3.7	50.6	22.1	90.9	25.7	61.4		48.9 ^b	41.4	26.7	2.3	71.5
Burkina Faso	Becauey, 2019 (39)	40.5	53.8	8.1	53.0	15.4						49.6	63.8	41.1	45.7
Ghana	Adu-Afarwuah, 2007 (40); Adu-Afarwuah, 2008 (9)	9.2	29.0	88.3	52.1	40.0			18.1	59.3		46.3	91.9	91.5	57.7
Ghana	Adu-Afarwuah, 2016 (41); Adu-Afarwuah, 2019 (16)	15.3	39.0	78.8	48.2	33.7	35.3	8.2	45.4	63.3	30.3 ^b	50.1	98.4	97.2	59.2
Kenya	Null, 2018 (42); Stewart, 2019 (12)	21.6	40.9	46.3	47.8	18.9			49.2	11.6	11.7 ^b	43.9	70.1	13.4	27.3
Madagascar	Galasso, 2019 (43); Stewart, 2020 (13)		47.0	22.8	47.6	23.0			43.3		28.4 ^b	49.0	26.4	0.0	88.7
Malawi	Ashorn, 2015 (44)	40.0	50.2	15.7	47.4	20.8	65.7	8.4	68.9	33.2	71.6 ^b	46.7	91.5	9.4	70.8
Malawi	Maleta, 2015 (45)	25.8	45.2	24.4	50.8	23.7	62.7	5.7	67.9		73.9 ^b	49.2	91.8	2.9	59.4
Mali	Huybregts, 2019 (46)	27.5	47.5	10.6	52.3	14.4						49.7	59.7	74.9	100.0
Zimbabwe	Humphrey, 2019 (HIV-unexposed) (47)	15.4	47.6	96.4	50.2	26.7		5.6	21.0	57.0	18.7 ^c	49.3	62.6	33.3	92.6
Zimbabwe	Prendergast, 2019 (HIV-exposed) (48)	18.1	22.9	94.3	49.9	19.7		8.4	15.5	54.3	25.1 ^c	49.3	61.8	30.6	93.7

Abbreviations: BMI, body mass index; SES, socio-economic status

Notes:
 Anemia: Hemoglobin < 110 g/L
 Baseline hemoglobin and anthropometric status (acute malnutrition) were measured at enrollment into the study or start of supplementation if supplementation did not begin at enrollment. These data are not available for studies with a repeated cross-sectional survey design, as the same individual children were not included in both baseline and endline surveys.
 Acute malnutrition: weight-for-length Z-score < -2 SD or mid-upper arm circumference < 125 mm
 High-dose vitamin A: received in 6 months prior to outcome assessment (yes/no)
 Food security scales used: a) Food Access Survey Tool; b) Household Food Insecurity Access Scale (HFAIS); c) Coping Strategy Index
 Water and sanitation references - as for study-level effect modifiers
 Season is defined at time of outcome assessment as a dichotomous "Rainy" vs "Dry" category based on child-specific average rainfall during the month of measurement and 2 months prior. In Mali (Huybregts 2019), there was little variation in rainfall during the endline cross-sectional survey, as it was conducted in the dry season (February-March).
 *Data on birth order were not available for all children. Consequently, first-born vs later-born status was estimated based on the number of children under 5 years old in the household.

Supplemental Table S: Description of biochemical assessments

Country	Author	Hemoglobin (Hb)		Micronutrient status biomarkers							Inflammation biomarkers		
		Hb sample	Hb method	MN sample	Ferritin	sTfR	ZPP	Zinc	Retinol	RBP	CRP	AGP	Malaria
Bangladesh	Christian, 2015 (35); Campbell, 2020 (15)	Venous	Hemocue Hb 301	Venous, serum	Automated chemiluminescent immunoassay (Immulate 2000)	-----	-----	Graphite furnace AAS	Reverse-phase HPLC	-----	Automated chemiluminescent assay (Immulate 2000)	Radial immunodiffusion (Kent Laboratories)	-----
Bangladesh	Dewey, 2017 (36); Matias, 2018 (10)	Capillary	Hemocue Hb 301	Capillary, serum	Combined sandwich ELISA	Combined sandwich ELISA	-----	-----	-----	Combined sandwich ELISA	Combined sandwich ELISA	Combined sandwich ELISA	-----
Bangladesh	Luby, 2018 (37); Stewart, 2019 (12)	Venous	Hemocue Hb 301	Venous, serum	Combined sandwich ELISA	Combined sandwich ELISA	-----	-----	-----	Combined sandwich ELISA	Combined sandwich ELISA	Combined sandwich ELISA	Y
Burkina Faso	Hess, 2015 (38); Abbeduto 2017 (11)	Capillary	Hemocue HB 201+	Venous, plasma	Combined sandwich ELISA	Combined sandwich ELISA	Hematofluorometer (Aviv Biomedical); washed RBC	ICP-AES	-----	Combined sandwich ELISA	Combined sandwich ELISA	Combined sandwich ELISA	RDT (Bioline Malaria Ag P.f/Pan)
Burkina Faso	Becquey, 2019 (39)	Capillary	Hemocue HB 201+	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
Ghana	Adu-Afarwuah, 2007 (40); Adu-Afarwuah, 2008 (9)	Venous	Hemocue B-Hemoglobin	Venous, plasma	Coat-A-Count Immunoradiometric Assay Kit (Diagnostic Products)	ELISA (Ramco Laboratories)	-----	ICP-AES	Reverse-phase HPLC	-----	Radial immunodiffusion (Binding Site)	-----	Blood smear (Giemsa stain)
Ghana	Adu-Afarwuah, 2016 (41); Adu-Afarwuah, 2019 (16)	Venous	Hemocue Hb 301	Venous, plasma	-----	-----	Hematofluorometer (Aviv Biomedical); washed RBC	-----	Reverse-phase HPLC	-----	Radial immunodiffusion (Binding Site)	Cobas Integra 400 plus Automatic Analyzer (Roche); particle-enhanced turbidimetric assay	RDT (Clearview Malarial Combo, Vision Biotech; HRP2 and P.aldolase)
Kenya	Null, 2018 (42); Stewart, 2019 (12)	Venous	Hemocue Hb 301	Venous, serum	Combined sandwich ELISA	Combined sandwich ELISA	-----	-----	-----	Combined sandwich ELISA	Combined sandwich ELISA	Combined sandwich ELISA	RDT (Aere; SD Bioline Malaria Ag P.f/P.v)
Madagascar	Galasso, 2019 (43); Stewart, 2020 (13)	Capillary	Hemocue Hb 301	Capillary, serum	Combined sandwich ELISA	Combined sandwich ELISA	-----	-----	-----	Combined sandwich ELISA	Combined sandwich ELISA	Combined sandwich ELISA	-----
Malawi	Ashorn, 2015 (44)	Capillary	Hemocue HB 201+	Venous, plasma	-----	-----	Hematofluorometer (Aviv Biomedical); washed RBC	-----	Reverse-phase HPLC	-----	Combined sandwich ELISA	Cobas Integra 400 plus Automatic Analyzer (Roche); particle-enhanced turbidimetric assay	RDT
Malawi	Maleta, 2015 (45)	Capillary	Hemocue HB 201+	-----	-----	-----	Hematofluorometer (Aviv Biomedical); washed RBC	-----	-----	-----	Combined sandwich ELISA	Cobas Integra 400 plus Automatic Analyzer (Roche); particle-enhanced turbidimetric assay	RDT
Mali	Huybrechts, 2019 (46)	Capillary	Hemocue HB 201+	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
Zimbabwe	Humbrey, 2019 (47); Prendergast 2019 (48)	Venous	Hemocue Hb 301 ¹	Venous, plasma	-----	-----	-----	-----	-----	-----	-----	-----	-----

AAS, atomic absorption spectroscopy; AGP, alpha-1-acid glycoprotein; CRP, C-reactive protein; Hb, hemoglobin; HPLC, high performance liquid chromatography; ICP-AES, inductively coupled plasma atomic emission spectroscopy; MN, micronutrient; RBC, red blood cells; RBP, retinol binding protein; RDT, rapid diagnostic test; sTfR, soluble transferrin receptor; ZPP, zinc protoporphyrin

¹Hemoglobin data were altitude adjusted (27)

Supplemental Table 6: Biomarker outcomes at endline among control groups, by trial

Country	Author	Anemia, Hb < 110		Moderate to severe	Iron deficiency,		Iron deficiency		ZPP > 70		Plasma zinc, µg/dL	Zinc < 65 µg/dL	Retinol, µmol/L	Retinol < 0.70 µmol	Retinol < 1.05 µmol	RBP, µmol	RBP < 0.70 µmol	RBP < 1.05 µmol
		Hemoglobin, g/L	g/L	anemia, Hb < 100 g/L	Ferritin, µg/L	ferritin < 12 µg/L	anemia	sTfR, mg/L	sTfR > 8.3 mg/L	ZPP, µmol/mol heme								
Bangladesh	Christian, 2015 (35); Campbell, 2020 (15)	118 ± 9	15.8	1.4	23.4 (13.2, 37.2)	22.2	9.0											
Bangladesh	Dewey, 2017 (36); Meites, 2018 (10)	112 ± 14	41.9	16.5	21.1 (12.8, 32.0)	22.1	14.7	8.3 (7.0, 11.3)	50.0		88.3 (80.2, 99.8)	2.1	1.35 (1.10, 1.70)	2.9	19.4	1.19 (1.01, 1.44)	3.3	29.0
Bangladesh	Luby, 2018 (37); Stewart, 2019 (12)	118 ± 9	16.1	3.2	15.9 (8.9, 25.6)	35.4	10.1	7.5 (6.2, 8.6)	31.5							1.14 (0.96, 1.35)	1.1	35.4
Burkina Faso	Hess, 2015 (38); Abbeduto, 2017 (11)	89 ± 16	91.1	75.0	9.7 (6.2, 18.6)	58.5	54.5	9.9 (6.6, 12.6)	61.3	122.2 (70.7, 181.1)						1.06 (0.89, 1.20)	8.5	49.1
Burkina Faso	Beccroev, 2019 (39)	103 ± 13	70.1															
Ghana	Adu-Afarwuah, 2007 (40); Adu-Afarwuah, 2008 (9)	106 ± 15	58.3	32.3														
Ghana	Adu-Afarwuah, 2016 (41); Adu-Afarwuah, 2019 (16)	112 ± 11	44.9	5.4	9.3 (3.2, 29.1)	56.1	35.4	9.6 (7.4, 12.8)	62.2		60.0 (53.9, 68.4)	68.1	1.08 (0.80, 1.33)	16.2	48.6			
Kenya	Nuli, 2018 (42); Stewart, 2019 (12)	110 ± 13	47.3	21.3	10.1 (6.3, 16.7)	59.1	33.3	10.9 (8.2, 15.5)	79.0							0.97 (0.80, 1.16)	9.3	59.5
Madagascar	Galasso, 2019 (43); Stewart, 2020 (13)	104 ± 16	64.8	32.8	11.6 (9.3, 18.5)	51.0	27.5	9.0 (7.2, 13.5)	58.8							1.09 (0.95, 1.28)	2.0	39.2
Malawi	Ashorn, 2015 (44)	108 ± 15	51.9	23.6						53.6 (36.1, 85.1)			1.05 (0.87, 1.20)	9.2	48.5			
Malawi	Maketa, 2015 (45)	101 ± 14	72.0	46.3						66.4 (40.1, 110.4)								
Mali	Haybrecht, 2019 (46)	95 ± 13	86.2	60.2														
Zimbabwe	Humphrey, 2019 (HIV-unexposed) (47)	114 ± 12	35.3	10.6	NA			NA										
Zimbabwe	Prendergast, 2019 (HIV-exposed) (48)	115 ± 13	36.8	10.2	NA			NA										

Hb, hemoglobin; NA, data not yet available; RBP, retinol binding protein; sTfR, soluble transferrin receptor; ZPP, zinc protoporphyrin

Values are mean ± SD, median (IQR) or prevalences

All continuous biomarkers, with the exception of hemoglobin, were natural log transformed prior to analysis

Ferritin, sTfR, zinc, retinol and RBP concentrations were adjusted for inflammation (i.e., C-reactive protein (CRP) and/or α-1-acid glycoprotein (AGP) concentrations, as available), using a regression correction approach adapted from the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project (28)